• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

    10/7/25 8:00:00 AM ET
    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENGN alert in real time by email

    Equity Insider News Commentary

    Issued on behalf of GT Biopharma, Inc.

    VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring development of targeted platforms that activate natural killer cells, enhance radiation effects, detect disease earlier, and deploy bispecific antibodies against previously undruggable targets[5]. Clinical-stage developers advancing these differentiated mechanisms include GT Biopharma, Inc. (NASDAQ:GTBP), I-Mab (NASDAQ:IMAB), enGene Holdings Inc. (NASDAQ:ENGN), Onconetix, Inc. (NASDAQ:ONCO), and Nanobiotix S.A. (NASDAQ:NBTX).

    Equity Insider Logo (PRNewsfoto/Equity Insider)

    With HHS doubling federal funding for cancer research to $100 million[6] and multiple companies reporting pivotal trial data across blood cancers, gastric malignancies, bladder cancer, pancreatic detection, and esophageal tumors, institutional capital is flowing toward platforms addressing the 60-70% of patients who don't respond to standard checkpoint inhibitors. The convergence of immune activation technologies, precision diagnostics, gene therapies, and nanoparticle-enhanced radiation creates favorable conditions for early-positioned companies with clinical-stage assets proving efficacy in historically resistant cancer types before major consolidation accelerates in these emerging categories.

    GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage immunotherapy company making significant progress in its fight against difficult-to-treat cancers. The San Francisco-based biotech has been advancing its lead drug candidate, GTB-3650, through a Phase 1 clinical trial targeting blood cancers that have stopped responding to other treatments. In August, the company successfully moved into Cohort 3 after formal safety reviews of the first two patient groups showed no safety or tolerability problems. The trial had treated five patients by mid-August, with encouraging early signals of immune system activation.

    "We are pleased with the enrollment momentum in our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which continues to advance on schedule," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "Moving into the third dose cohort after a successful safety review and encouraging early evidence of immunological activity, mark important steps forward in the development of GTB-3650. We look forward to sharing more data later this year to reinforce the ability of our TriKE constructs to activate endogenous NK cells, and the potential for broader utility with other targets to treat solid tumors (GTB-5550) and autoimmune indications (GTB-7550)."

    The Phase 1 trial is testing GTB-3650 in patients with relapsed or refractory CD33-expressing blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These are patients whose cancers have come back or never responded to standard therapies. The drug works by activating the body's own natural killer cells to attack cancer cells. Patients receive the treatment through continuous infusions in two-week cycles, alternating two weeks on and two weeks off, for up to four months based on how well they're responding.

    What makes the early data particularly interesting is the biomarker evidence. Multiple blood tests from the first four patients showed measurable increases in natural killer cell activity and expansion. This suggests the drug is doing exactly what it was designed to do—wake up the immune system and direct it against cancer. GT Biopharma expects to release more detailed Phase 1 results later this year after completing additional dose cohorts.

    Beyond blood cancers, GT Biopharma has a second drug candidate moving toward the clinic. GTB-5550 targets a protein called B7H3 that appears in many different types of solid tumors, including breast, lung, ovarian, head and neck, pancreatic, bladder, and prostate cancers. The company expects to submit its application to start human testing of GTB-5550 during the fourth quarter of this year. Unlike many cancer immunotherapies that require lengthy hospital infusions, GTB-5550 is being developed as a simple injection that patients could potentially give themselves at home, similar to insulin shots.

    Both drug candidates are built on GT Biopharma's proprietary TriKE platform, which uses specialized antibody fragments originally discovered in camels and llamas. These molecules are smaller and more stable than traditional antibodies, allowing them to work more effectively. GT Biopharma holds an exclusive worldwide license from the University of Minnesota to develop and commercialize therapies using this technology.

    As of June 30, 2025, GT Biopharma reported cash and cash equivalents of approximately $5.3 million, which management expected would fund operations into the first quarter of 2026.

    CONTINUED… Read this and more news for GT Biopharma, Inc. at: 

    https://equity-insider.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/

    I-Mab (NASDAQ:IMAB) has announced accelerated investment in givastomig, its lead Claudin 18.2-directed bispecific antibody, with plans to initiate a global randomized Phase 2 study in first-line metastatic gastric cancers in Q1 2026. The company expects to report Phase 1b dose expansion data in Q1 2026 and is expanding development into additional Claudin 18.2-positive tumor types including biliary tract cancer and pancreatic ductal adenocarcinoma.

    "2025 has been a year of significant progress for I-Mab. Compelling Phase 1b combination data and positive investigator engagement have accelerated the givastomig program and reinforced our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for metastatic gastric cancers in the 1L setting," said Sean Fu, PhD, CEO of I-Mab. "Based on these accomplishments, we are expanding our investment in givastomig, with plans to initiate a randomized Phase 2 study in Q1 2026."

    I-Mab appointed Wei Fu as Executive Chairman and Dr. Sean Cao as Chief Business Development Officer to support the company's growth initiatives. With cash and marketable securities of $224.9 million expected to fund operations into 2027, the company is positioned to advance its precision immuno-oncology pipeline through multiple clinical milestones.

    enGene Holdings Inc. (NASDAQ:ENGN) achieved target enrollment of 100 patients in the pivotal cohort of its LEGEND Phase 2 trial evaluating detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company was granted Regenerative Medicine Advanced Therapy designation by the FDA and plans to provide a data update from the pivotal cohort in 4Q 2025, positioning for a Biologics License Application submission in 2H 2026.

    "Reaching target enrollment in LEGEND's pivotal Cohort 1 and securing RMAT designation are important milestones that mark our continued momentum," said Ron Cooper, CEO of enGene Holdings Inc. "We look forward to providing a data update from the LEGEND pivotal cohort later this year. These advances bring us closer to our planned BLA filing in 2026 with the ultimate goal of delivering detalimogene to patients as a therapy designed for efficacy, safety, and ease-of-use."

    The company reported third quarter 2025 net loss of $28.9 million, or $0.57 per share, driven by increased manufacturing and clinical costs related to the LEGEND study. With cash, cash equivalents and marketable securities of $224.9 million as of July 31, 2025, enGene expects to fund operating expenses and capital expenditures into 2027.

    Onconetix, Inc. (NASDAQ:ONCO) announced that its wholly owned subsidiary Proteomedix has signed a licensing agreement with Immunovia AB to provide manufacturing intellectual property for the PancreaSure pancreatic cancer test. Under the agreement, Immunovia will make payments totaling $700,000 to Proteomedix in 2025 and 2026, plus a 3% royalty on net sales of PancreaSure from 2026 to 2032.

    "We are proud to have contributed to the development of PancreaSure and are excited to now support its manufacturing," said Beat Rheiner, PhD, CEO of Proteomedix. "Earlier detection of pancreatic cancer through PancreaSure gives patients real hope for better outcomes."

    The licensing agreement enables Immunovia to independently produce antibodies related to three of the five biomarkers included in PancreaSure while Onconetix continues to focus on commercializing Proclarix, its CE-certified in vitro diagnostic test for prostate cancer. Proteomedix will provide master cells and key manufacturing intellectual property to support the production of reagents for the pancreatic cancer diagnostic test.

    Nanobiotix S.A. (NASDAQ:NBTX) reported first Phase 1 data from its dose escalation study evaluating JNJ-1900 (NBTXR3) in 13 patients with locally advanced esophageal adenocarcinoma, demonstrating an 85% disease control rate and 69% objective response rate with 6 complete responses and 3 partial responses. The treatment, which combines hafnium oxide nanoparticles activated by radiotherapy with concurrent chemotherapy, was well-tolerated with the recommended Phase 2 dose established at 33% of gross tumor volume for photon chemoradiation.

    "Esophageal cancer remains one of the most difficult contexts for both patients and clinicians, where existing standards of care can create significant burdens for patients," said Louis Kayitalire, Chief Medical Officer at Nanobiotix. "We believe that JNJ-1900 (NBTXR3), through its broadly applicable mechanism of action, could offer a novel approach—one designed to enhance local control and potentially reduce the need for highly invasive procedures such as esophagectomy."

    The study, sponsored by The University of Texas MD Anderson Cancer Center, is actively recruiting 17 additional patients for dose escalation and expansion cohorts evaluating both photon and proton chemoradiation followed by surgery.

    Nanobiotix is developing JNJ-1900 (NBTXR3) in collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, with the potential to expand into new indications for locally advanced esophageal cancer and additional activation modalities beyond standard radiation therapy.

    Article Sources: https://equity-insider.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Equity Insider on behalf of Market IQ Media Group Inc. ("MIQ"). MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of GT Biopharma, Inc. but reserve the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of GT Biopharma, Inc. by CDMG; this is a paid advertisement, we currently own shares of GT Biopharma, Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    SOURCES CITED:

    1. https://www.prnewswire.com/news-releases/astellas-to-present-pioneering-advances-across-its-portfolio-and-pipeline-at-esmo-2025-302571874.html
    2. https://www.prnewswire.com/news-releases/eisai-highlights-breadth-of-oncology-research-at-esmo-2025-featuring-5-year-survival-data-from-study-309keynote-775-302573253.html 
    3. https://www.onclive.com/view/inside-the-most-anticipated-lung-cancer-abstracts-what-to-expect-from-esmo-2025 
    4. https://www.curetoday.com/view/all-fda-oncology-approvals-from-september-2025 
    5. https://www.sciencedaily.com/releases/2025/09/250921091002.htm 
    6. https://www.nih.gov/news-events/news-releases/hhs-doubles-ai-backed-childhood-cancer-research-funding 

    Logo: https://mma.prnewswire.com/media/2644233/5549294/Equity_Insider_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novel-cancer-platforms-converge-as-clinical-data-reshapes-treatment-paradigms-302576956.html

    SOURCE Equity Insider

    Get the next $ENGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENGN
    $GTBP
    $IMAB
    $NBTX

    CompanyDatePrice TargetRatingAnalyst
    I-MAB
    $IMAB
    10/3/2025$9.00Outperform
    Leerink Partners
    I-MAB
    $IMAB
    9/9/2025$7.00Buy
    BTIG Research
    enGene Holdings Inc.
    $ENGN
    2/18/2025$26.00Overweight
    Piper Sandler
    enGene Holdings Inc.
    $ENGN
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    enGene Holdings Inc.
    $ENGN
    12/23/2024$25.00Buy
    H.C. Wainwright
    GT Biopharma Inc.
    $GTBP
    12/2/2024$11.00Buy
    ROTH MKM
    enGene Holdings Inc.
    $ENGN
    11/27/2024$23.00Outperform
    Raymond James
    enGene Holdings Inc.
    $ENGN
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Sweiti Hussein

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/25 4:54:55 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sweiti Hussein

    3 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/25 4:53:25 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mun-Gavin David C.

    4 - GT Biopharma, Inc. (0000109657) (Issuer)

    9/8/25 5:45:44 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    11/1/24 4:15:08 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/18/24 4:15:05 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/24 8:02:44 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ:GTBP), Lexeo Therapeutics, Inc. (NASDAQ:LXEO), Anixa Biosciences, Inc. (NASDAQ:ANIX), Tempus AI, Inc. (NASDAQ:TEM)

    10/8/25 10:58:00 AM ET
    $ANIX
    $CTOR
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

    The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the previous two lower-dose cohorts; additional update anticipated by year-end Upon successful completion of the Cohort 3 safety assessment, the trial will continue to dose escalate with initiation of Cohort 4 dosing planned by year-end 2025, and flexibility to dose up to 7 cohorts if necessary; additional data updates anticipated in Q1 2026 SAN FRAN

    10/8/25 9:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop

    10/7/25 8:00:00 AM ET
    $ENGN
    $GTBP
    $IMAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    SEC Filings

    View All

    SEC Form D filed by Onconetix Inc.

    D - Onconetix, Inc. (0001782107) (Filer)

    10/7/25 5:14:02 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    10/6/25 7:00:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    10/3/25 8:16:13 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on I-Mab with a new price target

    Leerink Partners initiated coverage of I-Mab with a rating of Outperform and set a new price target of $9.00

    10/3/25 8:40:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on I-Mab with a new price target

    BTIG Research initiated coverage of I-Mab with a rating of Buy and set a new price target of $7.00

    9/9/25 7:57:49 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on enGene Holdings with a new price target

    Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

    2/18/25 7:08:31 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

    Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula

    9/30/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

    Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC)Mr. Wei Fu, I-Mab's Chairman of the Board of Directors, appointed as Executive Chairman, supported by further executive additions ROCKVILLE, Md., Sept. 08, 2025 (GLOBE N

    9/8/25 8:30:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

    Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of DirectorsResearch and Development Committee established to accelerate innovation and long-term growthDr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of

    8/25/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

    Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-

    9/17/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

    Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'

    9/11/25 4:03:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

    Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Cash and marketable securities of $251.5 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. "We have seen strong

    6/12/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    $GTBP
    $IMAB
    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 5:48:15 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 5:05:21 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care